Molecular Modeling on Pyrimidine-Urea Inhibitors of TNF-α Production: An Integrated Approach Using a Combination of Molecular Docking, Classification Techniques, and 3D-QSAR CoMSIA
暂无分享,去创建一个
George Kollias | Georgia Melagraki | Thomas M. Mavromoustakos | Varnavas D. Mouchlis | Antreas Afantitis | G. Kollias | G. Melagraki | A. Afantitis | T. Mavromoustakos | V. Mouchlis
[1] Haralambos Sarimveis,et al. A novel QSPR model for predicting θ (lower critical solution temperature) in polymer solutions using molecular descriptors , 2006, Journal of molecular modeling.
[2] Ajay N. Jain. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.
[3] Thomas M. Mavromoustakos,et al. Binding Conformation of 2-Oxoamide Inhibitors to Group IVA Cytosolic Phospholipase A2 Determined by Molecular Docking Combined with Molecular Dynamics , 2012, J. Chem. Inf. Model..
[4] Robert Newton,et al. Inhibitors of p38 mitogen-activated protein kinase: potential as anti-inflammatory agents in asthma? , 2003, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[5] G Melagraki,et al. Ligand and structure based virtual screening strategies for hit-finding and optimization of hepatitis C virus (HCV) inhibitors. , 2011, Current medicinal chemistry.
[6] M. Feldmann,et al. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.
[7] George Kollias,et al. The role of TNF/TNFR in organ-specific and systemic autoimmunity: implications for the design of optimized 'anti-TNF' therapies. , 2002, Current directions in autoimmunity.
[8] T. Mavromoustakos,et al. The application of rational design on phospholipase A(2) inhibitors. , 2011, Current medicinal chemistry.
[9] Bruce R. Kowalski,et al. Prediction of Product Quality from Spectral Data Using the Partial Least-Squares Method , 1984 .
[10] George Kollias,et al. In Silico Exploration for Identifying Structure–Activity Relationship of MEK Inhibition and Oral Bioavailability for Isothiazole Derivatives , 2010, Chemical biology & drug design.
[11] George Kollias,et al. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease , 1999, Immunological reviews.
[12] Georg Schett,et al. Cytokines in the pathogenesis of rheumatoid arthritis , 2007, Nature Reviews Immunology.
[13] Emilio Benfenati,et al. Simplified Molecular Input‐Line Entry System and International Chemical Identifier in the QSAR Analysis of Styrylquinoline Derivatives as HIV‐1 Integrase Inhibitors , 2011, Chemical biology & drug design.
[14] Nunzio Iraci,et al. Allosteric inhibition of the hepatitis C virus NS5B polymerase: in silico strategies for drug discovery and development. , 2011, Future medicinal chemistry.
[15] George Kollias,et al. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. , 2002, Cytokine & growth factor reviews.
[16] D E Griswold,et al. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. , 1996, The Journal of pharmacology and experimental therapeutics.
[17] G. Johnson,et al. Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases , 2002, Science.
[18] Jeremy R. Greenwood,et al. Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..
[19] Giuseppina C. Gini,et al. CORAL: Quantitative structure–activity relationship models for estimating toxicity of organic compounds in rats , 2011, J. Comput. Chem..
[20] C W Qualls,et al. Comparative Biochemical and Morphometric Changes Associated with Induction of the Hepatic Mixed Function Oxidase System in the Rat , 1991, Toxicologic pathology.
[21] Paola Gramatica,et al. The applications of machine learning algorithms in the modeling of estrogen-like chemicals. , 2009, Combinatorial chemistry & high throughput screening.
[22] Igor V Tetko,et al. A comparison of different QSAR approaches to modeling CYP450 1A2 inhibition , 2011, J. Chem. Inf. Model..
[23] Haralambos Sarimveis,et al. A novel simple QSAR model for the prediction of anti-HIV activity using multiple linear regression analysis , 2006, Molecular Diversity.
[24] D. E. Patterson,et al. Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .
[25] George Kollias,et al. A combined LS-SVM & MLR QSAR workflow for predicting the inhibition of CXCR3 receptor by quinazolinone analogs , 2010, Molecular Diversity.
[26] Thomas M. Mavromoustakos,et al. Molecular Docking and 3D-QSAR CoMFA Studies on Indole Inhibitors of GIIA Secreted Phospholipase A2 , 2010, J. Chem. Inf. Model..
[27] Haralambos Sarimveis,et al. A novel QSAR model for predicting induction of apoptosis by 4-aryl-4H-chromenes. , 2006, Bioorganic & medicinal chemistry.
[28] P. Limburg,et al. p38 mitogen-activated protein kinase (MAPK) in rheumatoid arthritis. , 2006, Mini reviews in medicinal chemistry.
[29] Biswanath De,et al. Development of N-2,4-pyrimidine-N-phenyl-N'-alkyl ureas as orally active inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 2. , 2006, Bioorganic & medicinal chemistry letters.
[30] E. Keystone,et al. Restricted cytokine expression in rheumatoid arthritis. , 1993, Arthritis and rheumatism.
[31] George Kollias,et al. Interleukin‐10 targets p38 MAPK to modulate ARE‐dependent TNF mRNA translation and limit intestinal pathology , 2001, The EMBO journal.
[32] G N Sastry,et al. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking. , 2008, European journal of medicinal chemistry.
[33] Paola Gramatica,et al. Development, Validation and Inspection of the Applicability Domain of QSPR Models for Physicochemical Properties of Polybrominated Diphenyl Ethers , 2009 .
[34] Matthew R. Lee,et al. MAP Kinase p38Inhibitors: Clinical Results and an Intimate Look at Their Interactions with p38α Protein , 2005 .
[35] George Kollias,et al. Predictive QSAR workflow for the in silico identification and screening of novel HDAC inhibitors , 2009, Molecular Diversity.
[36] Giovanni Camussi,et al. The Future Role of Anti-Tumour Necrosis Factor (TNF) Products in the Treatment of Rheumatoid Arthritis , 1998, Drugs.
[37] Alexander Golbraikh,et al. A Novel Automated Lazy Learning QSAR (ALL-QSAR) Approach: Method Development, Applications, and Virtual Screening of Chemical Databases Using Validated ALL-QSAR Models , 2006, J. Chem. Inf. Model..
[38] Wei Guo,et al. Characterization of the Structure and Function of a New Mitogen-activated Protein Kinase (p38β)* , 1996, The Journal of Biological Chemistry.
[39] J. Madwed,et al. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. , 2002, Journal of medicinal chemistry.
[40] Aixia Yan,et al. Prediction of biological activity of Aurora-A kinase inhibitors by multilinear regression analysis and support vector machine. , 2011, Bioorganic & medicinal chemistry letters.
[41] J. Gasteiger,et al. ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .
[42] William L. Jorgensen,et al. Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..
[43] C. Dinarello,et al. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases , 1991, Current Biology.
[44] N. Olsen,et al. New drugs for rheumatoid arthritis. , 2004, The New England journal of medicine.
[45] Knut Baumann,et al. Cross-validation as the objective function for variable-selection techniques , 2003 .
[46] Ian H. Witten,et al. The WEKA data mining software: an update , 2009, SKDD.
[47] M. Natália D. S. Cordeiro,et al. Two New Parameters Based on Distances in a Receiver Operating Characteristic Chart for the Selection of Classification Models , 2011, J. Chem. Inf. Model..
[48] Robert Newton,et al. Inhibitors of p38 Mitogen-Activated Protein Kinase , 2003, BioDrugs.
[49] William P. Purcell,et al. A brief review and table of semiempirical parameters used in the Hueckel molecular orbital method , 1967 .
[50] Y. Zhao,et al. Comparison of decision tree methods for finding active objects , 2007, 0708.4274.
[51] Varnavas D. Mouchlis,et al. Inhibition of secreted phospholipases A₂ by 2-oxoamides based on α-amino acids: Synthesis, in vitro evaluation and molecular docking calculations. , 2011, Bioorganic & medicinal chemistry.
[52] G Klebe,et al. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.
[53] Gerhard Klebe,et al. Comparative Molecular Similarity Index Analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries , 1999, J. Comput. Aided Mol. Des..
[54] L. Tong,et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket , 1997, Nature Structural Biology.
[55] George Kollias,et al. Ligand-based virtual screening procedure for the prediction and the identification of novel β-amyloid aggregation inhibitors using Kohonen maps and Counterpropagation Artificial Neural Networks. , 2011, European journal of medicinal chemistry.
[56] Thomas M. Mavromoustakos,et al. Design of new secreted phospholipase A2 inhibitors based on docking calculations by modifying the pharmacophore segments of the FPL67047XX inhibitor , 2010, J. Comput. Aided Mol. Des..
[57] G. M. Sperandio da Silva,et al. A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors. , 2004, Bioorganic & medicinal chemistry.
[58] Jahan B. Ghasemi,et al. QSAR Models for CXCR2 Receptor Antagonists Based on the Genetic Algorithm for Data Preprocessing Prior to Application of the PLS Linear Regression Method and Design of the New Compounds Using In Silico Virtual Screening , 2011, Molecules.
[59] Angelo Carotti,et al. Strategies of multi-objective optimization in drug discovery and development , 2011, Expert opinion on drug discovery.
[60] E. Goldsmith,et al. The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[61] Jerry L. Adams,et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.
[62] Yong Jiang,et al. Characterization of the Structure and Function of the Fourth Member of p38 Group Mitogen-activated Protein Kinases, p38δ* , 1997, The Journal of Biological Chemistry.
[63] M. Feldmann,et al. Cytokines in autoimmunity. , 1992, Current opinion in immunology.
[64] M. Feldmann,et al. Cytokines and anti-cytokine biologicals in autoimmunity: present and future. , 2002, Cytokine & growth factor reviews.
[65] Alexander Tropsha,et al. Modeling of p38 mitogen-activated protein kinase inhibitors using the Catalyst HypoGen and k-nearest neighbor QSAR methods. , 2004, Journal of molecular graphics & modelling.
[66] D E Griswold,et al. Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. , 1998, Bioorganic & medicinal chemistry letters.
[67] Paul R. Caron,et al. Crystal Structure of p38 Mitogen-activated Protein Kinase* , 1996, The Journal of Biological Chemistry.
[68] Hai-Long Wu,et al. Adaptive variable-weighted support vector machine as optimized by particle swarm optimization algorithm with application of QSAR studies. , 2011, Talanta.
[69] Srikanta Sen,et al. Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model. , 2011, European journal of medicinal chemistry.
[70] Lu Chen,et al. A Critical Assessment of Combined Ligand- and Structure-Based Approaches to hERG Channel Blocker Modeling , 2011, J. Chem. Inf. Model..
[71] Pramod C. Nair,et al. Quantitative structure activity relationship studies on thiourea analogues as influenza virus neuraminidase inhibitors. , 2008, European journal of medicinal chemistry.
[72] Haralambos Sarimveis,et al. Development and Evaluation of a QSPR Model for the Prediction of Diamagnetic Susceptibility , 2008 .
[73] Kunal Roy,et al. On various metrics used for validation of predictive QSAR models with applications in virtual screening and focused library design. , 2011, Combinatorial chemistry & high throughput screening.
[74] Biswanath De,et al. Development of N-2,4-pyrimidine-N-phenyl-N'-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 1. , 2006, Bioorganic & medicinal chemistry letters.
[75] Matthew R. Lee,et al. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. , 2005, Current medicinal chemistry.
[76] George Kollias,et al. The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease , 1999, Annals of the rheumatic diseases.
[77] Jiahuai Han,et al. The primary structure of p38 gamma: a new member of p38 group of MAP kinases. , 1996, Biochemical and biophysical research communications.
[78] S. Kassis,et al. p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials. , 1999, Pharmacology & therapeutics.
[79] Tobias Gabriel,et al. Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. , 2005, Current topics in medicinal chemistry.
[80] R. Friesner,et al. Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .
[81] M. Feldmann,et al. Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.
[82] Julio Caballero,et al. Genetic Algorithm Optimization in Drug Design QSAR: Bayesian‐Regularized Genetic Neural Networks (BRGNN) and Genetic Algorithm‐Optimized Support Vectors Machines (GA‐SVM) , 2011 .
[83] S. Wold,et al. A PLS kernel algorithm for data sets with many variables and fewer objects. Part 1: Theory and algorithm , 1994 .
[84] G. Klebe,et al. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.
[85] M. Jalali-Heravi,et al. QSAR study of heparanase inhibitors activity using artificial neural networks and Levenberg-Marquardt algorithm. , 2008, European journal of medicinal chemistry.
[86] R. Cramer,et al. Validation of the general purpose tripos 5.2 force field , 1989 .
[87] Jordi Bolós,et al. Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors. , 2005, Mini reviews in medicinal chemistry.